Britannia Life Sciences Inc.
BLSIF
$0.04
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.32% | -473.86% | -278.88% | -219.76% | -223.11% |
| Total Depreciation and Amortization | -13.11% | -45.60% | -59.63% | -59.44% | -49.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -35.31% | -- |
| Total Other Non-Cash Items | -80.93% | 215.36% | 248.03% | 285.31% | -40.71% |
| Change in Net Operating Assets | -98.70% | -85.83% | -29.12% | -3.29% | 1,104.17% |
| Cash from Operations | -197.65% | -124.53% | -63.25% | -50.99% | -56.97% |
| Capital Expenditure | -91.49% | -111.25% | 90.23% | 91.44% | 95.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -446.97% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,664.34% | -249.39% | -630.11% | -140.69% | -11.27% |
| Cash from Investing | -303.30% | 60.99% | 80.68% | 66.31% | -167.33% |
| Total Debt Issued | -100.00% | -- | -- | 3,197.01% | 3,197.01% |
| Total Debt Repaid | -20.62% | 35.60% | 56.12% | 30.80% | 19.88% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -11.25% | -- | -33.09% | -33.09% |
| Cash from Financing | 54.99% | 80.67% | 55.64% | 13.58% | 4.66% |
| Foreign Exchange rate Adjustments | -102.43% | 183.28% | 195.04% | -22.68% | -27.34% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -345.84% | 31.04% | 74.24% | -0.43% | -380.45% |